News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Policy
Celgene European Panel Recommends Against Revlimid for MDS
January 25, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
NEW YORK, Jan 24 (Reuters) - Celgene Corp said on Thursday an advisory panel for European health regulators recommended Revlimid not be approved in Europe for myelodysplastic syndrome patients with anemia, citing safety concerns.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
MORE ON THIS TOPIC
Government
Trump’s CDC Pick Says Vaccines Are Safe, Promises To Keep Them Available
June 26, 2025
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
Lilly-Verve Proxy Filing Reveals Tumult After Departure of FDA’s Marks
June 26, 2025
·
4 min read
·
Annalee Armstrong
Vaccines
RFK Cuts U.S. Funding From Vaccine Alliance Gavi, Claims Group ‘Ignored the Science’
June 26, 2025
·
2 min read
·
Tristan Manalac
Vaccines
What To Watch for as ACIP’s New Era Begins
June 25, 2025
·
3 min read
·
Dan Samorodnitsky